Figure 1.
In vivo characterization of 8803 in subcutaneous KPC-derived PDAC. (A) Mice received subcutaneous injection of 2.5×105 mT4-2D cells in 30% matrigel, then were injected intratumorally with 5 µg CDN on days 15, 18, and 21 before tumor harvest on day 23. Tumors were massed, counted, and processed for flow cytometry analysis as described in Methods. Data shown represent (B) tumor mass, (C) CD45+ infiltration, (D) overall composition of analyzed CD45+ cells, (E) cellular densities, (F) Ki67 and (G) Ly6C expression on tumor CD8 T cells, (H) normalized CD206 expression on macrophages, and (I) arginase expression in MO-MDSC. Data are cumulative of two independent experiments with five mice per group. Statistical significance was calculated using Student’s t-test. *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CDN, cyclic dinucleotide; MDSC, myeloid-derived suppressor cells; ns, not significant; PDAC, pancreatic adenocarcinoma.